Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rolofylline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 6/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.71 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.71 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.71 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rolofylline SCHEMBL720438 | 0.83 | ADORA1 (1.00) | ADORA2AADORA2BADORA1ADORA3SLC6A3 | |
| SCHEMBL7472412 | 0.79 | ADORA1 (0.51) | ADORA2AADORA2BADORA1ADORA3SLC6A3 | |
| SCHEMBL14051422 | 0.79 | ADORA1 (0.91) | ADORA2AADORA2BADORA1ADORA3SLC6A3 | |
| Rolofylline SCHEMBL13414155 | 0.78 | ADORA1 (0.88) | ADORA2AADORA2BADORA1ADORA3SLC6A3 | |
| SCHEMBL7269330 | 0.77 | ADORA2A (0.81) | ADORA2AADORA2BADORA1ADORA3SLC6A3 | |
| SCHEMBL8707422 | 0.77 | ADORA1 (0.86) | ADORA2AADORA2BADORA1ADORA3SLC6A3 | |
| SCHEMBL8705557 | 0.77 | ADORA1 (0.92) | ADORA2AADORA2BADORA1ADORA3SLC6A3 | |
| SCHEMBL7270718 | 0.76 | ADORA1 (1.00) | ADORA2AADORA2BADORA1ADORA3SLC6A3 | |
| Rolofylline SCHEMBL13414105 | 0.76 | ADORA1 (0.86) | ADORA2AADORA2BADORA1ADORA3SLC6A3 | |
| SCHEMBL8707145 | 0.76 | ADORA1 (0.84) | ADORA2AADORA2BADORA1ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648778-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | National Health Research Institutes (TW) | 2025-11-19 | — | — | EP | claimed |
| WO-2025073290-A1 | VPS4 INHIBITORS AND METHODS OF USE THEREOF | PARA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| WO-2024151651-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2024-07-18 | — | — | WO | claimed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | claimed |
| EP-4294844-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | Janssen Biotech, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | claimed |
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | claimed |
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | JANSSEN BIOTECH, INC. | 2022-09-01 | — | — | US | claimed |
| WO-2022175920-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-11324705-B2 | Transdermal drug delivery system | AVRO LIFE SCIENCES, INC. (CA) | 2022-05-10 | — | — | US | claimed |
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| US-12630560-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | NUVALENT, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-10696972-B2 | Method for improving learning | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180030453-A1 | METHOD FOR IMPROVING LEARNING | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030453-A1 | METHOD FOR IMPROVING LEARNING | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2016134091-A1 | METHOD FOR IMPROVING LEARNING | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ADORA1 36/4885ADORA2A 27/4885ADORA2B 28/4885 |
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | CD38, PARP1, PARP11 | ADORA1 25/4885ADORA2A 16/4885ADORA2B 38/4885 |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ADORA1 36/4885ADORA2A 27/4885ADORA2B 28/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | ADORA1 36/4885ADORA2A 27/4885ADORA2B 28/4885 |
| US-12630560-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | CYP2F1, CYP11B2, CYP7B1 | ADORA1 3394/4885ADORA2A 3726/4885ADORA2B 3407/4885 |
| US-20180030453-A1 | METHOD FOR IMPROVING LEARNING | NT5E, ADORA1, ENTPD5 | ADORA1 2/4885ADORA2A 4/4885ADORA2B 7/4885 |
| US-10696972-B2 | Method for improving learning | NT5E, ADORA1, ENTPD5 | ADORA1 2/4885ADORA2A 4/4885ADORA2B 7/4885 |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | HTR1D, HTR5A, PCNP | ADORA1 733/4885ADORA2A 859/4885ADORA2B 459/4885 |
| US-11324705-B2 | Transdermal drug delivery system | CUTA, AQP1, SLC26A4 | ADORA1 1766/4885ADORA2A 2115/4885ADORA2B 3147/4885 |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | FLNB, SETD1B, HTR5A | ADORA1 684/4885ADORA2A 610/4885ADORA2B 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.